All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

ASH 2023: Top abstracts in MM and other plasma cell dyscrasias

Nov 30, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article

To help navigate the exciting content being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

Newly diagnosed multiple myeloma


Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients

Francesca Gay


Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients: Final results of the phase 2 study IFM 2018-04

Cyrille Touzeau


Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: First results of the phase 2 EMN26 study

Niels W.C.J. van de Donk


GEM2017FIT trial: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) Plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: Phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) Patients aged between 65 and 80 years

Maria-Victoria Mateos


Minimally invasive assessment of measurable residual disease (MRD) in multiple myeloma (MM)

Carmen Gonzalez


Mass spectrometry-based assessment of M-Protein in peripheral blood during maintenance therapy in multiple myeloma (MM) in the phase III ATLAS trial

Tadeusz Kubicki


Dynamic frailty status enables better prediction of survival probability - results of the HOVON 143 study

Febe Smits


Longitudinal screening of mutant hematopoietic progenitor cells (HPC) in multiple myeloma (MM) and its association with secondary primary malignancies (SPM)

Cristina Perez


Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD)

Nisha S. Joseph


Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 fastcar-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

Juan Du


Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the determination phase 3 trial

Jeffrey A. Zonder


Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (Pts) with Newly diagnosed multiple myeloma (NDMM) Who are eligible for autologous stem cell transplantation (ASCT): Primary results of the Perseus trial

Pieter Sonneveld

Relapsed and/or refractory multiple myeloma


Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma

Danai Dima


BMS-986393 (CC-95266), a G protein–coupled receptor class C group 5 member D (GPRC5D)–targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 study

Susan Bal


Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed/refractory multiple myeloma: Updated analyses of minimal residual disease negativity in phase 1/2 study

Nizar J. Bahlis


Efficacy outcomes and characteristics of patients with multiple myeloma (MM) Who achieved sustained minimal residual disease negativity after treatment with equecabtagene autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li


Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA Myeloma XII (ACCoRD)

Gordon Cook


Randomized phase 3 study of pomalidomide cyclophosphamide dexamethasone (PCD) Versus pomalidomide dexamethasone (PD) in relapse or refractory myeloma: An Asian Myeloma Network (AMN) study

Wee-Joo Chng


Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study

Ajai Chari


Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach


Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial

Paul G. Richardson


Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: Safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study

Jeffrey V. Matous


The phase 2 CARTITUDE-2 trial: Updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)

Jens Hilengrass


Real world outcomes with idecabtagene vicleucel (Ide-Cel) CAR-T cell therapy for relapsed/refractory multiple myeloma

Surbhi Sidana


Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3

Paula Rodríguez Otero


Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to t-cell redirecting therapies: Results of the phase 1/2 MonumenTAL-1 study

Andrzej J. Jakubowiak


Alternative Lymphodepletion strategies lead to similar response rates and toxicities in standard-of-care BCMA-directed CAR-T therapy in relapsed refractory multiple myeloma

Shonali Midha

Other plasma cell dyscrasias

Top abstracts by region

In addition to the top abstracts selected by our steering committee, the Multiple Myeloma Hub would like to highlight some key region-specific abstracts in the field of multiple myeloma and plasma cell dyscrasias.

Latin America

Asia Pacific

Europe, the Middle East and Africa

ASH 2023 abstracts

To download this document, click below.

Download here


Subscribe to get the best content related to multiple myeloma delivered to your inbox